SEC Comment Letter for Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687) (RNAC) — Feb 4, 2020
Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687)
Date: Feb. 4, 2020 · CIK: 0001453687 · Accession: 0000000000-20-001078
AI Filing Summary & Sentiment
File numbers found in text: 333-236147
Letter
February 4, 2020 Carsten Brunn, Ph.D. President and Chief Executive Officer Selecta Biosciences, Inc. 480 Arsenal Way Watertown, MA 02472 Re:Selecta Biosciences, Inc. Registration Statement on Form S-3 Filed January 29, 2020 File No. 333-236147 Dear Dr. Brunn: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Peter N. Handrinos, Esq.
Show Raw Text
February 4, 2020
Carsten Brunn, Ph.D.
President and Chief Executive Officer
Selecta Biosciences, Inc.
480 Arsenal Way
Watertown, MA 02472
Re:Selecta Biosciences, Inc.
Registration Statement on Form S-3
Filed January 29, 2020
File No. 333-236147
Dear Dr. Brunn:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Peter N. Handrinos, Esq.